University of Hawaii licenses Diversa patent for DNA sequence-based discovery from environmental sources.
The license of the environmental DNA sequencing technology is the second one to be announced by Diversa. In May 2003, the United States Department of Energy's Joint Genome Institute signed a license agreement with Diversa as part of a large-scale microbial sequencing collaboration. Under the collaboration, Diversa uses its proprietary technologies to extract DNA from environmental samples and construct gene libraries that can contain essentially all of the genes of over 10,000 unique microbes, referred to as "metagenome libraries." JGI is primarily responsible for sequencing the DNA from these libraries. JGI is one of the world's largest capacity gene sequencing centers and played a vital role in the publicly funded Human Genome Project.
"This license is part of a broader, mutually beneficial relationship we have established with the University of Hawaii involving potential new products and scientific discoveries from unique Hawaiian environments," stated Jay M. Short, Ph.D., Diversa's President and Chief Executive Officer. "At the same time that Diversa is fostering basic academic research, this license leverages our product discovery capabilities by providing Diversa with commercial access to new genes identified by the academic researchers. We expect that other institutions that are interested in microbial community metagenomic sequencing will follow the lead of the Department of Energy and the University of Hawaii and seek a license to Diversa's patented technology."
"The University of Hawaii is extremely excited to be working with Diversa Corporation and we are grateful for Diversa's support of our scientific and educational efforts related to the discovery of unique genetic materials from the rich biodiversity found in Hawaii," said Dr. Robert Bidigare, Director of the UH Center for Marine Microbial Ecology and Diversity. "Not only will the licensing of this technology provide our faculty, researchers, and students with access to new genomic tools that they need to continue and expand their work, but it will also prove beneficial in our current efforts to establish the university as a collaborator in industry research and a contributor to the economic diversification of our state."
The claims of the licensed patent include, among others, a claim directed to "a method of obtaining a nucleic acid encoding a polypeptide comprising: sequencing a plurality of nucleic acids selected at random from a nucleic acid library generated randomly from the genomes of a plurality of members of a mixed population of organisms or more than one organism; and performing a database search to compare sequences of the randomly selected nucleic acids to sequences in the database."
Diversa is a leader in applying proprietary genomic technologies for the rapid discovery and optimization of novel protein-based products. Diversa is directing its integrated portfolio of technologies to the discovery, evolution, and production of commercially valuable molecules with pharmaceutical applications, such as optimized monoclonal antibodies and orally active drugs, as well as enzymes and small molecules with agricultural, chemical, and industrial applications. Diversa has established alliances and joint ventures with market leaders, such as Amgen, BASF, Bayer Animal Health, The Dow Chemical Company, DSM Pharma Chemicals, DuPont Bio-Based Materials, Givaudan Flavors Corporation, GlaxoSmithKline plc, Invitrogen Corporation, Medarex, and XOMA. In addition, Diversa has formed a broad strategic relationship with Syngenta AG, a world-leading agribusiness company. Diversa has commercialized products both independently and in collaboration with strategic partners and licensees.
|Printer friendly Cite/link Email Feedback|
|Comment:||University of Hawaii licenses Diversa patent for DNA sequence-based discovery from environmental sources.|
|Publication:||BIOTECH Patent News|
|Date:||Oct 1, 2004|
|Previous Article:||Bristol-Myers Squibb Medical Imaging and IMCOR Pharmaceutical enter into cross-licensing agreement for ultrasound contrast patents.|
|Next Article:||Benitec grants ddRNAi license to Artemis for development of transgenics.|